Prospective Grant of Exclusive License: Use of Thymosin β4 for Wound Healing Applications; Correction
Department of Health and Human Services National Institutes of Health The notice published in the February 28, 2000 Federal Register -announcing the prospective grant of an excl...
The notice published in the February 28, 2000
Federal Register
—announcing the prospective grant of an exclusive license for use of thymosin β4 for wound healing applications (65 FR 10505)—incorrectly listed one of the serial numbers for the subject invention as “60/094,960” under the
SUMMARY
section. NIH is publishing this notice to correct this serial number to read “60/094,690.” In view of this correction, to allow interested parties adequate time to respond, the
DATES
section is also amended to read “Only written comments and/or license applications
( printed page 13014)
which are received by the National Institutes of Health on or before June 8, 2000 will be considered.”
Dated: March 6, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of Technology Transfer.
Use this for formal legal and research references to the published document.
65 FR 13013
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive License: Use of Thymosin β4 for Wound Healing Applications; Correction,” thefederalregister.org (March 10, 2000), https://thefederalregister.org/documents/00-5785/prospective-grant-of-exclusive-license-use-of-thymosin-4-for-wound-healing-applications-correction.